{
    "Trade/Device Name(s)": [
        "MammaPrint\u00ae"
    ],
    "Submitter Information": "Agendia BV",
    "510(k) Number": "K101454",
    "Predicate Device Reference 510(k) Number(s)": [
        "K081092"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "December 23, 2010",
    "Summary Letter Received Date": "December 27, 2010",
    "Submission Date": "May 21, 2010",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [
        "Fresh breast cancer tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MammaPrint microarray",
        "Micro Array Scanners",
        "Bioanalyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray-based gene expression analysis",
        "RNA isolation",
        "cRNA labeling",
        "Hybridization",
        "Feature extraction"
    ],
    "Methodologies": [
        "Gene expression profiling"
    ],
    "Submission Type(s)": [
        "Test",
        "Service",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Agendia MammaPrint microarray-based gene expression profiling service for breast cancer prognosis risk assessment",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test using gene expression profile of fresh breast cancer tissue to assess risk for distant metastasis in Stage I or II, lymph node-negative patients with tumors \u22645.0 cm, intended as a prognostic marker used alongside other clinicopathological factors",
    "fda_folder": "Immunology"
}